• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Benefit of early initiation of neuraminidase inhibitor treatment to hospitalized patients with avian influenza A (H7N9) virus

tetano

Editor, Senior Moderator
Clin Infect Dis. 2017 Oct 25. doi: 10.1093/cid/cix930. [Epub ahead of print]
[h=1]Benefit of early initiation of neuraminidase inhibitor treatment to hospitalized patients with avian influenza A (H7N9) virus.[/h] Zheng S[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Wang Y[SUP]2,[/SUP][SUP]3[/SUP], Yu F[SUP]2,[/SUP][SUP]3[/SUP], Cui D[SUP]2,[/SUP][SUP]3[/SUP], Xie G[SUP]2,[/SUP][SUP]3[/SUP], Yang X[SUP]2,[/SUP][SUP]3[/SUP], Zhang W[SUP]2,[/SUP][SUP]3[/SUP], Ye X[SUP]2,[/SUP][SUP]3[/SUP], Zhang Z[SUP]2,[/SUP][SUP]3[/SUP], Wang X[SUP]4[/SUP], Liang Y[SUP]5[/SUP], Zhang Y[SUP]5[/SUP], Gao H[SUP]5[/SUP], Yang S[SUP]5[/SUP], Tang L[SUP]5[/SUP], Liang W[SUP]5[/SUP], Li L[SUP]5[/SUP], Yu C[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]Background:[/h] The significance of early neuraminidase inhibitor (NAI) therapy for treating influenza A(H7N9) is currently unknown.
[h=4]Methods:[/h] The duration of viral shedding was monitored by RT-PCR after patients with confirmed H7N9 infection were admitted to the First Affiliated Hospital, Zhejiang University during April 2013 to April 2017. Indices such as the length of hospitalization and mortality were collected, and the correlation between the time of administration of NAI and the severity of disease was systematically analyzed.
[h=4]Results:[/h] 160 patients with confirmed H7N9 infection were divided into three groups according to NAI starting time. 3 (15%) out of 20 patients for whom NAI was administered within 2 days died compared with 12 (23.1%) out of 52 patients who received treatment within 2-5 days and 33 (37.5%) out of 88 patients who were treated after 5 days (P<0.05). The median durations of viral shedding from NAI therapy initiation was 4.5 days (interquartile range (IQR): 3-9) for patients who took antiviral medication within 2 days, which was significantly different from that for patients who took medication within 2-5 days (7.5 days,IQR: 4.25-12.75) or after 5 days (7days, IQR: 5-10) (P<0.05). We found that the duration of viral shedding from NAI therapy was the shortest of 5.5 days in spring 2013 and the longest of 8.5 days in winter-spring 2016-17 (P<0.05), showing a prolonged trend.
[h=4]Conclusions:[/h] Early NAI therapy within 2 days of illness shorten the duration of viral shedding and improve survival in patients with H7N9 viral infections.


[h=4]KEYWORDS:[/h] H7N9; Influenza; neuraminidase inhibitor treatment; viral shedding

PMID: 29077848 DOI: 10.1093/cid/cix930
 
Back
Top Bottom